|
1
|
Nix P, Nicolaides A and Coatesworth AP:
Thyroid cancer review 1: Presentation and investigation of thyroid
cancer. Int J Clin Pract. 59:1340–1344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ito Y, Nikiforov YE, Schlumberger M and
Vigneri R: Increasing incidence of thyroid cancer: Controversies
explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lalami Y and Awada A: Recurrent thyroid
cancer: A molecular-based therapeutic breakthrough. Curr Opin
Oncol. 23:235–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Albero A, Lopéz JE, Torres A, de la Cruz L
and Martín T: Effectiveness of chemotherapy in advanced
differentiated thyroid cancer: A systematic review. Endocr Relat
cancer. 23:R71–R84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giuffrida D and Gharib H: Current
diagnosis and management of medullary thyroid carcinoma. Ann Oncol.
9:695–701. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pelizzo MR, Boschin IM, Bernante P,
Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC and
Rubello D: Natural history, diagnosis, treatment and outcome of
medullary thyroid cancer: 37 years experience on 157 patients. Eur
J Surg Oncol. 33:493–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA
and Chen H: Overexpression of the NOTCH1 intracellular domain
inhibits cell proliferation and alters the neuroendocrine phenotype
of medullary thyroid cancer cells. J Biol Chem. 281:39819–39830.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sippel RS, Kunnimalaiyaan M and Chen H:
Current management of medullary thyroid cancer. Oncologist.
13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tavares MR, Toledo SP, Montenegro FL,
Moyses RA, Toledo RA, Sekyia T, Cernea CR and Brandão LG: Surgical
approach to medullary thyroid carcinoma associated with multiple
endocrine neoplasia type 2. Clinics (Sao Paulo). 67(Suppl 1):
S149–S154. 2012. View Article : Google Scholar
|
|
10
|
Ball DW: Medullary thyroid cancer:
Monitoring and therapy. Endocrinol Metab Clin North Am. 36:823–837.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brassard M and Rondeau G: Role of
vandetanib in the management of medullary thyroid cancer.
Biologics. 6:59–66. 2012.PubMed/NCBI
|
|
12
|
Machens A, Lorenz K and Dralle H:
Individualization of lymph node dissection in RET (rearranged
during transfection) carriers at risk for medullary thyroid cancer:
Value of pretherapeutic calcitonin levels. Ann Surg. 250:305–310.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tavares MR, Michaluart P Jr, Montenegro F,
Arap S, Sodre M, Takeda F, Brandao L, Toledo S and Ferraz A: Skip
metastases in medullary thyroid carcinoma: A single-center
experience. Surg Today. 38:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun L, Kokura K, Izumi V, Koomen JM, Seto
E, Chen J and Fang J: MPP8 and SIRT1 crosstalk in E-cadherin gene
silencing and epithelial-mesenchymal transition. EMBO Rep.
16:689–699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsumoto-Taniura N, Pirollet F, Monroe R,
Gerace L and Westendorf JM: Identification of novel M phase
phosphoproteins by expression cloning. Mol Biol Cell. 7:1455–1469.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Murata K, Sato S, Haruta M, Goshima T,
Chiba Y, Takahashi S, Sharif J, Koseki H, Nakanishi M and Shimada
M: Physical interaction between MPP8 and PRC1 complex and its
implication for regulation of spermatogenesis. Biochem Biophys Res
Commun. 458:470–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kokura K, Sun L, Bedford MT and Fang J:
Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing
and promotes tumour cell motility and invasion. EMBO J.
29:3673–3687. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang Y, Sun L, Kokura K, Horton JR,
Fukuda M, Espejo A, Izumi V, Koomen JM, Bedford MT, Zhang X, et al:
MPP8 mediates the interactions between DNA methyltransferase Dnmt3a
and H3K9 methyltransferase GLP/G9a. Nat Commun. 2:5332011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishigaki M, Kawada Y, Misaki T, Murata K,
Goshima T, Hirokawa T, Yamada C, Shimada M and Nakanishi M: Mitotic
phosphorylation of MPP8 by cyclin-dependent kinases regulates
chromatin dissociation. Biochem Biophys Res Commun. 432:654–659.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Antonelli A, Fallahi P, Ferrari SM,
Ruffilli I, Santini F, Minuto M, Galleri D and Miccoli P: New
targeted therapies for thyroid cancer. Curr Genomics. 12:626–631.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sipos JA and Shah MH: Thyroid cancer:
Emerging role for targeted therapies. Ther Adv Med Oncol. 2:3–16.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Russo D, Damante G, Puxeddu E, Durante C
and Filetti S: Epigenetics of thyroid cancer and novel therapeutic
targets. J Mol Endocrinol. 46:R73–R81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kokura K, Sun L, Bedford MT and Fang J:
Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing
and promotes tumour cell motility and invasion. EMBO J.
29:3673–3687. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–8. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manjunath N, Wu H, Subramanya S and
Shankar P: Lentiviral delivery of short hairpin RNAs. Adv Drug
Deliv Rev. 61:732–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
